Cambridge Antibody Technology (CAT) has promoted three individuals to the management position of vice president. Gaynor Fryers has been named vice president, business development and will be responsible for managing the company’s business development activities. Ms. Fryers joined the company in 2004, and prior to her promotion, held the position of business development director. Before joining CAT, she worked as group commercial director at Bespak and held a number of business and commercial roles at Bio Products Laboratory (BPL).

Ian Anderson will serve as vice president, discovery – respiratory and inflammation. He will lead the respiratory and inflammation team within CAT’s drug discovery department. Mr. Anderson joined the company in 1998 to establish the pharmacology group and previously worked at Glaxo Wellcome in a number of roles within the pharmacology and neuroscience departments.

Andy Williams, named vice president, discovery – program management, will lead the program management team within CAT’s drug discovery department. He joined the company in 1993, following a post-doctoral fellowship at the University of British Columbia in Vancouver, and has led a number of CAT’s drug discovery and technology development projects.

Hamish Cameron, chief executive officer at CAT, commented, “CAT’s progression as a world-leading biopharmaceutical company is underpinned by the knowledge and expertise of our exceptional staff. These key promotions will strengthen and broaden the capabilities and experience of our team and we are delighted to recognize the expertise of these three individuals and their contribution to CAT’s ongoing success.”